To this end, we employed primary CD20+HER2/neu+, CD20+HER2/neu− and CD20−HER2/neu− ALL blasts (non-cultured PBMC from ALL patients with a percentage of leukemic cells > 80%) in cytotoxicity assays with pNKC. Here, ERBB2 is linked to acute lymphoblastic leukemia.